CARDIFF ONCOLOGY, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- CARDIFF ONCOLOGY, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $105.00K, a 3400.00% increase year-over-year.
- CARDIFF ONCOLOGY, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $25.00K.
- CARDIFF ONCOLOGY, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-03-31 was $3.00K, a 97.20% decline year-over-year.
- CARDIFF ONCOLOGY, INC. stock issued during period, value, stock options exercised for the quarter ending 2024-06-30 was $253.00K.
- CARDIFF ONCOLOGY, INC. stock issued during period, value, stock options exercised for fiscal 2025 was $493.00K, a 32.17% increase from fiscal 2024.
- CARDIFF ONCOLOGY, INC. stock issued during period, value, stock options exercised for fiscal 2024 was $373.00K.
- CARDIFF ONCOLOGY, INC. stock issued during period, value, stock options exercised for fiscal 2020 was $148.00K.
- CARDIFF ONCOLOGY, INC. stock issued during period, value, stock options exercised for fiscal 2016 was $366.97K, a 57.37% decline from fiscal 2015.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-03-31 | $105.00K 10-Q · filed 2026-08-11 | |
| 2025-12-31 | $493.00K 10-K · filed 2026-02-24 | |
| 2025-09-30 | $25.00K 10-Q · filed 2025-11-06 | |
| 2025-03-31 | $3.00K 10-Q · filed 2026-08-11 | |
| 2024-12-31 | $373.00K 10-K · filed 2026-02-24 | |
| 2024-06-30 | $253.00K 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $107.00K 10-Q · filed 2025-11-06 | |
| 2022-09-30 | $75.00K 10-Q · filed 2023-11-02 | |
| 2020-12-31 | $148.00K 10-K · filed 2022-02-24 | |
| 2020-09-30 | $7.00K 10-Q · filed 2021-11-04 | |
| 2016-12-31 | $366.97K 10-K · filed 2018-02-26 | |
| 2015-12-31 | $860.85K 10-K · filed 2017-03-15 | |
| 2013-12-31 | $38.25K 10-K · filed 2016-03-10 | |
| 2012-12-31 | $600.00 10-K · filed 2015-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |